Health ❯ Healthcare ❯ Clinical Trials

Phase 3 Trials

Efficacy Studies Eli Lilly Trials Efficacy and Safety Drug Efficacy Eli Lilly C-POST Trial Randomised Controlled Trials EPCORE FL-1 Trial Vaccine Efficacy DESTINY-Breast09 Trial

3 ARTICLES

2w ago

BioNTech’s Gotistobart Nearly Doubles Median Survival in Late-Stage Lung Cancer Trial

The company says the updated Phase 3 data show a large survival gain that must be confirmed in the next part of the trial before it can alter treatment standards.

3 ARTICLES

2w ago

Amivantamab Plus Chemotherapy Shows Longest Survival for EGFR Exon 20 Insertion Lung Cancer

8 ARTICLES

3w ago

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

21 ARTICLES

last mo.

Moderna and Merck Say Phase 3 Personalized mRNA Melanoma Vaccine Met Key Endpoints

26 ARTICLES

last mo.

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

119 ARTICLES

last mo.

Moderna and Merck Report Positive Phase 3 Results for Personalized Melanoma Vaccine

7 ARTICLES

last mo.

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

12 ARTICLES

2mo ago

FDA Panel Rejects Deramiocel Cardiac Claim After Lancet Publishes HOPE‑3 Results

3 ARTICLES

2mo ago

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

3 ARTICLES

2mo ago

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

4 ARTICLES

2mo ago

Serum Institute to Build Capacity to Make Investigational TB Vaccine for Gates MRI

5 ARTICLES

2mo ago

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

5 ARTICLES

2mo ago

FDA Grants Accelerated Approval to Trutakna for IgA Nephropathy

3 ARTICLES

3mo ago

FDA Approves Lumvoa for Thyroid Eye Disease

6 ARTICLES

3mo ago

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

3 ARTICLES

3mo ago

FDA Expands Capvaxive Use to At‑Risk Children and Teens

Phase 3 Trials

BioNTech’s Gotistobart Nearly Doubles Median Survival in Late-Stage Lung Cancer Trial

Amivantamab Plus Chemotherapy Shows Longest Survival for EGFR Exon 20 Insertion Lung Cancer

AstraZeneca's Tozorakimab Cuts COPD Flare‑Ups in Two Phase 3 Trials

FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera

Aficamten Improves Symptoms and Exercise Capacity in Nonobstructive HCM

FDA Approves Lisraya as First Oral Treatment for Adult Dermatomyositis

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

Moderna and Merck Say Phase 3 Personalized mRNA Melanoma Vaccine Met Key Endpoints

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

Moderna and Merck Report Positive Phase 3 Results for Personalized Melanoma Vaccine

Never miss stories about

Phase 3 Trials

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

FDA Panel Rejects Deramiocel Cardiac Claim After Lancet Publishes HOPE‑3 Results

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

Serum Institute to Build Capacity to Make Investigational TB Vaccine for Gates MRI

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

FDA Grants Accelerated Approval to Trutakna for IgA Nephropathy

FDA Approves Lumvoa for Thyroid Eye Disease

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

FDA Expands Capvaxive Use to At‑Risk Children and Teens

Never miss stories about

Phase 3 Trials